You just read:

MGB Biopharma Announces Promising Phase IIa Clinical Trial Update for MGB-BP-3, a Novel, Potent Bactericidal Antibiotic Targeting Clostridium difficile-Associated Diarrhoea (CDAD)

News provided by

MGB Biopharma

Oct 10, 2019, 05:30 ET